Pancreatic and non-pancreatic causes of hyperamylasemia
https://doi.org/10.31146/1682-8658-ecg-244-12-18-27
Abstract
Elevated serum amylase levels are typically associated with acute and chronic pancreatitis, but pancreatitis is not the only cause of hyperamylasemia. Pancreatic imaging may not reveal any changes. A wide range of repeated diagnostic and therapeutic measures are used to lower amylase levels, but this is not always successful, and amylase levels do not return to normal. A patient may have no clinical symptoms of acute or chronic pancreatitis and may not require treatment, yet still undergo multiple laboratory and imaging studies and repeated treatment courses. This article discusses the possible causes of hyperamylasemia, which may be caused not only by pancreatic diseases but also by diseases of other organs and systems.
About the Authors
E. A. Dubtsova
The Loginov Moscow Clinical Scientific Center (MCSC) funded by Moscow Health Department
Russian Federation
Russian Federation
L. V. Vinokurova
The Loginov Moscow Clinical Scientific Center (MCSC) funded by Moscow Health Department
Russian Federation
Russian Federation
D. S. Bordin
The Loginov Moscow Clinical Scientific Center (MCSC) funded by Moscow Health Department; Russian University of Medicine Moscow
Russian Federation
Russian Federation
References
1. Pieper-Bigelow C., Strocchi A., Levitt M.D. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am. 1990 Dec;19(4):793-810.
2. Frulloni L., Patrizi F., Bernardoni L., Cavallini G. Pancreatic hyperenzymemia: clinical significance and diagnostic approach. JOP. 2005 Nov 10;6(6):536-51.
3. Gallucci F., Buono R., Ferrara L., Madrid E., Miraglia S., Uomo G. Chronic asymptomatic hyperamylasemia unrelated to pancreatic diseases. Adv Med Sci. 2010;55(2):143-5. doi: 10.2478/v10039-010-0049-9.
4. Seyama K., Nukiwa T., Takahashi K., Takahashi H., Kira S. Amylase mRNA transcripts in normal tissues and neoplasms: implication of different expressions of amylase isogenes. J. Cancer Res. Clin. Oncol. 1994;120:213-222. doi: 10.1007/BF01372559.
5. Koda Y.K., Vidolin E. Familial hyperamylasemia. Rev Hosp Clin Fac Med Sao Paulo. 2002 Mar-Apr; 57(2):77-82. doi: 10.1590/s0041-87812002000200006.
6. Acute pancreatitis. Clinical guidelines of the Russian Federation. 2024. (in Russ.)@@ Острый панкреатит. Клинические рекомендации РФ 2024 г.
7. Clavien P.A., Robert J., Meyer P., Borst F., Hauser H., Herrmann F., Dunand V., Rohner A. Acute pancreatitis and normoamylasemia. Not an uncommon combination. Ann Surg. 1989 Nov;210(5):614-20. doi: 10.1097/00000658-198911000-00008.
8. Yadav D., Agarwal N., Pitchumoni C.S. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol. 2002 Jun;97(6):1309-18. doi: 10.1111/j.1572-0241.2002.05766.x.
9. Mortelé K.J., Wiesner W., Zou K.H., Ros P.R., Silverman S.G. Asymptomatic nonspecific serum hyperamylasemia and hyperlipasemia: spectrum of MRCP findings and clinical implications. Abdom Imaging. 2004 Jan-Feb;29(1):109-14. doi: 10.1007/s00261-003-0072-4.
10. Li G.Z., Wang F., Fang J., Zha H.L., Zhao Q. Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Evidence from 1786 Cases. Med Sci Monit. 2018 Nov 26;24:8544-8552.
11. Christoforidis E., Goulimaris I., Kanellos I., Tsalis K., Demetriades C., Betsis D. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy. 2002 Apr;34(4):286-92. doi: 10.1055/s-2002-23630.
12. Kapetanos D., Kokozidis G., Kinigopoulou P., Xiarchos P., Antonopoulos Z., Progia E., Kitis G. The value of serum amylase and elastase measurements in the prediction of post-ERCP acute pancreatitis. Hepatogastroenterology. 2007 Mar;54(74):556-60.
13. Lam R., Muniraj T. Hyperamylasemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2022 Dec 11. PMID: 32644699
14. Chen C.C., Chen S.Y., Chen Y.S., Lo C.Y., Cheng P.W. Mycobacterium fortuitum-induced persistent parotitis: successful therapy with clarithromycin and ciprofloxacin. Head Neck. 2007 Nov;29(11):1061-4. doi: 10.1002/hed.20626.
15. Gokel Y., Gulalp B., Acikalin A. Parotitis due to organophosphate intoxication. J Toxicol ClinToxicol. 2002;40(5):563-5. doi: 10.1081/clt-120014648.
16. Krasnovsky A.L., Grigoriev S.P., Zolkina I.V., Loshkareva E.O., Brutskaya L.A., Bykova E.A. Asymptomatic pancreatic hyperfermentemia.Russian Medical Journal. 2014;(5):52-56. (in Russ.)@@ Красновский А.Л., Григорьев С.П., Золкина И.В., Лошкарева Е.О., Бруцкая Л.А., Быкова Е.А. Бессимптомная панкреатическая гиперферментемия. Российский медицинский журнал. 2014. - № 5. - С. 52-56
17. Pezzilli R., Andreone P., Morselli-Labate A.M. et al. Serum pancreatic enzyme concentrations in chronic viral liver diseases. Dig Dis Sci. 1999 Feb;44(2):350-5. doi: 10.1023/a:1026662719514.
18. Katz S., Bank S., Greenberg R.E., Lendvai S., Lesser M., Napolitano B. Hyperamylasemia in inflammatory bowel disease. J Clin Gastroenterol. 1988 Dec;10(6):627-30. doi: 10.1097/00004836-198812000-00010.
19. Tromm A., Höltmann B., Hüppe D., Kuntz H.D., Schwegler U., May B. Hyperamylasemia, hyperlipasemia and acute pancreatitis in chronic inflammatory bowel diseases. Leber Magen Darm. 1991 Jan;21(1):15-6, 19-22.
20. Bokemeyer B. Asymptomatic elevation of serum lipase and amylase in conjunction with Crohn’s disease and ulcerative colitis. Z Gastroenterol. 2002 Jan;40(1):5-10. doi: 10.1055/s-2002-19636.
21. Pitchumoni C.S., Rubin A., Das K. Pancreatitis in inflammatory bowel diseases. J Clin Gastroenterol. 2010 Apr;44(4):246-53. doi: 10.1097/MCG.0b013e3181cadbe1.
22. Meczker Á., Mikó A., Gede N., Szentesi A., Párniczky A., Gódi S., Hegyi P; Hungarian Pancreatic Study Group Retrospective Matched-Cohort Analysis of Acute Pancreatitis Induced by 5-Aminosalicylic Acid-Derived Drugs. Pancreas. 2019 Apr;48(4):488-495. doi: 10.1097/MPA.0000000000001297.
23. Nitsche C.J., Jamieson N., Lerch M.M., Mayerle J.V. Drug induced pancreatitis. Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):143-55. doi: 10.1016/j.bpg.2010.02.002.
24. Tsujii Y., Nishida T., Osugi N. et al. Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study. Scand J Gastroenterol. 2022 Feb;57(2):190-196. doi: 10.1080/00365521.2021.1998601.
25. Weiss M.J., Edmondson H.A., Wertman M. Elevated serum amylase associated with bronchogenic carcinoma; report of case. Am.J. Clin. Pathol. 1951;21:1057-1061. doi: 10.1093/ajcp/21.11.1057.
26. Tsunashima T., Arima T., Onashi J. Hyperamylasemia in a case of ovarian cancer. Nihon Shokakibyo Gakkai Zasshi. 1976;73:907-909.
27. Joseph J., Viney S., Beck P., Strange C., Sahn S.A., Basran G.S. A prospective study of amylase-rich pleural effusions with special reference to amylase isoenzyme analysis. Chest. 1992;102:1455-9.
28. Maeda M., Otsuki M., Yuu H., Saeki S., Yamasaki T., Baba S. Salivary-type hyperamylasemia in primary lung cancer: observation of a possible precursor of the salivary-type isoamylase. Eur J Cancer Clin Oncol. 1982 Feb;18(2):123-8. doi: 10.1016/0277-5379(82)90054-2.
29. Benedetti G., Rastelli F., Damiani S., Calandri C., Crinò L. Challenging problems in malignancy: case 1. Presentation of small-cell lung cancer with marked hyperamylasemia. J Clin Oncol. 2004 Sep 15;22(18):3826-8. doi: 10.1200/JCO.2004.11.099.
30. Ko H.W., Tsai Y.H., Yu C.T., Huang C.Y., Chen C.H. Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: a case report. Chang Gung Med J. 2008 Nov-Dec;31(6):606-11.
31. Sinha S., Khan H., Timms P.M., Olagbaiye O.A. Pancreatic-type hyperamylasemia and hyperlipasemia secondary to ruptured ovarian cyst: a case report and review of the literature. J Emerg Med. 2010 May;38(4):463-6. doi: 10.1016/j.jemermed.2008.04.042.
32. Kawakita T., Sasaki H., Hoshiba T., Asamoto A., Williamson E. Amylase-producing ovarian carcinoma: A case report and a retrospective study. Gynecol Oncol Case Rep. 2012 Jun 17;2(3):112-4. doi: 10.1016/j.gynor.2012.06.002.
33. Srivastava R., Murphy M.J., Fraser C.G. Malignancy-associated hyperamylasaemia. Ann Clin Biochem. 2014 Sep;51(Pt 5):619. doi: 10.1177/0004563214531402.
34. Vinicor F., Lehrner L.M., Karn R.C., Merritt A.D. Hyperamylasemia in diabetic ketoacidosis: sources and significance. Ann Intern Med. 1979 Aug;91(2):200-4. doi: 10.7326/0003-4819-91-2-200.
35. Yadav D., Nair S., Norkus E.P., Pitchumoni C.S. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am J Gastroenterol. 2000 Nov;95(11):3123-8. doi: 10.1111/j.1572-0241. 2000.03279.x.
36. Sayiner Z.A., Inan Demiroğlu G., Akarsu E., Araz M. The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients. Turk J Pharm Sci. 2020 Feb;17(1):68-73. doi: 10.4274/tjps.galenos.2018.83788.
37. Sarathi V., Tirupati S., Sabinkar G., Mohan R. Hyperamylasemia is not Associated with Dipeptidyl Peptidase 4 Inhibitors in South Indian Adults with Type 2 Diabetes Mellitus.Int J Appl Basic Med Res. 2023 Apr-Jun;13(2):113-116. doi: 10.4103/ijabmr.ijabmr_503_22.
38. Argiris A., Mathur-Wagh U., Wilets I., Mildvan D. Abnormalities of serum amylase and lipase in HIV-positive patients. Am J Gastroenterol. 1999; 94:1248 doi: 10.1111/j.1572-0241.1999.01074.x.
39. Yoffe B., Bagri A.S., Tran T., Dural A.T., Shtenberg K.M., Khaoustov V.I. Hyperlipasemia associated with hepatitis C virus. Dig Dis Sci. 2003 Aug;48(8):1648-53. doi: 10.1023/a:1024744613671.
40. Kim S.Y., Kim J.H., Kim C.H. et al. A case of pheochromocytoma with hyperamylasemia. Korean J Gastroenterol. 2003 Aug;42(2):172-5.
41. Guruprasad C.S., Reghu K.S., Nair M., Kumary P.K. Asymptomatic Hyperamylasemia / Hyperlipasemia due to Pancreatic Infiltration in Acute Lymphoblastic Leukemia. Indian J Pediatr. 2016 Jan;83(1):81-2. doi: 10.1007/s12098-015-1754-y.
42. Sinha S., Khan H., Timms P.M., Olagbaiye O.A. Pancreatic-type hyperamylasemia and hyperlipasemia secondary to ruptured ovarian cyst: a case report and review of the literature. J Emerg Med. 2010 May;38(4):463-6. doi: 10.1016/j.jemermed.2008.04.042.
43. Pezzilli R., Andreone P., Morselli-Labate A.M. et al. Serum pancreatic enzyme concentrations in chronic viral liver diseases. Dig Dis Sci. 1999 Feb;44(2):350-5. doi: 10.1023/a:1026662719514.
44. Vaziri N.D., Chang D., Malekpour A., Radaht S. Pancreatic enzymes in patients with end-stage renal disease maintained on hemodialysis. Am J Gastroenterol. 1988 Apr;83(4):410-2.
45. Araki T., Ueda M., Taketa K., Kosaka K. Pancreatic-type hyperamylasemia in end-stage renal disease. Dig Dis Sci. 1989 Sep;34(9):1425-7. doi: 10.1007/BF01538080.
46. Frick T.W., Fryd D.S., Sutherland D.E., Goodale R.L., Simmons R.L., Najarian J.S. Hypercalcemia associated with pancreatitis and hyperamylasemia in renal transplant recipients. Data from the Minnesota randomized trial of cyclosporine versus antilymphoblast azathioprine. Am J Surg. 1987 Nov;154(5):487-9. doi: 10.1016/0002-9610(87)90260-1.
47. Galasso PJ, Litin SC, O’Brien JF. The macroenzymes: a clinical review. Mayo Clin Proc. 1993 Apr;68(4):349-54. doi: 10.1016/s0025-6196(12)60129-3.
48. Gallucci F, Madrid E, Esposito P, Uomo G. Association of macroamylasemia and type I macro-creatine kinasemia. A case report. JOP. 2007 Sep 7;8(5):605-8.
49. Wilding P., Cooke W.T., Nicholson G.I. Globulin”bound amylase. Ann.Intern. Med. 1964;(64):1053-1056.
50. Berk J.E., Kizu H., Wilding P., Searcy R.L. Macroamylasemia: a newly recognized cause for elevated serum amylase activity. N Engl J Med. 1967 Nov 2;277(18):941-6. doi: 10.1056/NEJM196711022771801.
51. Sakallıoğlu O. Macroamylasemia; a dilemma in morbidity. Balkan Med J. 2015 Jul;32(3):330. doi: 10.5152/balkanmedj.2015.15320.
52. Galasso PJ, Litin SC, O’Brien JF. The macroenzymes: a clinical review. Mayo Clin Proc. 1993 Apr;68(4):349-54. doi: 10.1016/s0025-6196(12)60129-3.
53. Goto H, Wakui H, Komatsuda A, Imai H, Miura AB, Fujita K. Simultaneous macroamylasemia and macrolipasemia in a patient with systemic lupus erythematosus in remission.Intern Med. 2000 Dec;39(12):1115-8. doi: 10.2169/internalmedicine.39.1115.
54. Klonof D.C. Macroamylasemia and other immunoglobulin-complexed enzyme disorders. West J Med. 1980 Nov;133(5):392-407.
55. Türkçapar N., Ozden A. Macroenzymes. Güncel Gastroenterology. 2005;9:161-6.
56. Türkçapar N, Ozyüncü N, Idilman R, Ensari A, Soylu K, Ozden A. Macroamylasemia in a patient with selective IgA deficiency and antiphospholipid antibodies. Turk J Gastroenterol. 2006;17:140-3.
57. Torrent Vernetta A, Segarra Canton O. Macroamylasemia in Peadiatrics. An Pediatr (Barc). 2008;69:439-41. doi: 10.1157/13127999.
58. Čásenská J, Franeková J, Mačinga P, Jabor A. Significant elevations of serum amylase caused by macroamylase: Case reports and detection possibilities. J Clin Lab Anal. 2023 Mar;37(5): e24859. doi: 10.1002/jcla.24859.
59. Barera G, Bazzigaluppi E, Viscardi M, Renzetti F, Bianchi C, Chiumello G, Bosi E. Macroamylasemia attributable to gluten related amylase autoantibodies: A case report. Pediatrics. 2001;107: E93. doi: 10.1542/peds.107.6.e93.
60. Sagristani M, Guariglia R, Pocali B, De Rienzo M, Guastafierro S, Romano G, Tirelli A. Macroamylasemia in a patient with multiple myeloma. Leuk Lymphoma. 2002 Aug;43(8):1705-7. doi: 10.1080/1042819021000003081.
61. Machida T, Shizuka R, Yabe S, Kobayashi Y, Yomoda S, Sawamura M, Murakami M. Identification of amylase-binding monoclonal immunoglobulins in multiple myeloma associated with macroamylasemia. Leuk Lymphoma. 2012 Nov;53(11):2293-5. doi: 10.3109/10428194.2012.682310.
62. Zaman Z, Van Orshoven A, Mariën G, Fevery J, Blanckaert N. Simultaneous macroamylasemia and macrolipasemia. Clin Chem. 1994 Jun;40(6):939-42.
63. Garcia-Gonzalez M., Defarges-Pons V., Monescillo A., Hernandez F., Cano-Ruiz A. Macrolipasemia and celiac disease. Am J Gastroenterol. 1995 Dec;90(12):2233-4.
64. Rabsztyn A., Green P.H., Berti I., Fasano A., Perman J.A., Horvath K. Macroamylasemia in patients with celiac disease. Am J Gastroenterol. 2001 Apr;96(4):1096-100. doi: 10.1111/j.1572-0241.2001.03746.x.
65. Nikolskaya K.A., Bordin D.S., Vinokurova L.V., Malykh M.V., Dubtsova E.A. Hyperamylasemia - is it always pancreatitis? Pharmateca. 2019; 26(2): 130-35. (in Russ.) doi: 10.18565/pharmateca.2019.2.130-135.@@ Никольская К.А., Бордин Д.С., Винокурова Л.В., Малых М.В., Дубцова Е.А. Гиперамилаземия - всегда ли это панкреатит? Фарматека. 2019; 26(2): 130-35. doi: 10.18565/pharmateca 2019.2.130-135.
66. Goto H, Wakui H, Komatsuda A, Imai H, Miura AB, Fujita K. Simultaneous macroamylasemia and macrolipasemia in a patient with systemic lupus erythematosus in remission.Intern Med. 2000 Dec;39(12):1115-8. doi: 10.2169/internalmedicine.39.1115.
67. Miyasaka K, Okamoto M, Hayashi M, Kuyama Y, Okada H, Furukawa Y, Momoi H. A case of pancreatic type hyperamylasemia associated with systemic lupus erythematosus - especially about mechanisms and incidence of P-type hyperamylasemia in SLE (author’s transl). Nihon Shokakibyo Gakkai Zasshi. 1979 Nov;76(11):2286-91.
68. Aoki A, Hagiwara E, Atsumi Y, Shirai A, Igarashi T, Narita M, Matsunaga K, Ishigatsubo Y, Tani K, Okubo T. A case report of macroamylasemia with rheumatoid arthritis. Ryumachi. 1989 Jun;29(3):207-12.
69. Greenberg RE, Bank S, Singer C. Macroamylasaemia in association with the acquired immunodeficiency syndrome. Postgrad Med J. 1987 Aug;63(742):677-9. doi: 10.1136/pgmj.63.742.677.
70. Ganesh M, Salam I. Lessons to be learned: a case study approach - acute appendicitis masquerading as macroamylasaemia. J R Soc Promot Health. 2008 May;128(3):140-2. doi: 10.1177/1466424008089796.
71. Dreiling DA, Leichtling JJ, Janowitz HD. The amylase-creatinine clearance ratio. Diagnostic parameter or physiologic phenomenon? Am J Gastroenterol. 1974 Apr;61(4):290-6.
72. Gubergrits N.B., Lukashevich G.M., Zagorenko Yu.A. Macroamylasemia - a harmless misconception or dangerous ignorance? Modern gastroenterology. 2006; 6 (32):93-99. (in Russ.)@@ Губергриц Н.Б., Лукашевич Г.М., Загоренко Ю.А. Макроамилаземия - безобидное заблуждение или опасное незнание? Сучасна гастроентерологія. 2006; 6 (32):93-99.
73. Beşer OF, Laçinel S, Gülcü D, Kutlu T, Cullu Çokuğraş F, Erkan T. An easy method for diagnosing macro-aspartate aminotransferase: a case series. Turk J Gastroenterol. 2014;25:568-570. doi: 10.5152/tjg.2014.7504.
74. Ono S, Kurata C, Nishimura N, et al. Importance of laboratory detection of macro-aspartate aminotransferase.Int J Gen Med. 2019;12:433-436. doi: 10.2147/IJGM.S224281.
75. Berk J.E. Macroamylasemia // Bockus gastroenterology. - 5. ed. - Philadelphia, 1995. - Vol. 4. - P. 2851-2860.
76. Mifflin T.E., Forsman R.W., Bruns D.E.Interaction of immo” bilized anti”salivary amylase antibody with human macroamyla” ses: implications for use in a pancreatic amylase assay to distin” guish macroamylasemia from acute pancreatitis. Clin Chem. 1989 Aug;35(8):1651-4.
77. Gullo L. Chronic nonpathological hyperamylasemia of pancreatic origin. Gastroenterology. 1996; Jun;110(6):1905-8. doi: 10.1053/gast.1996.v110.pm8964417.
78. Gullo L. Familial pancreatic hyperenzymemia. Pancreas. 2000 Mar;20(2):158-60. doi: 10.1097/00006676-200003000-00008.
79. Gullo L. Day-to-day variations of serum pancreatic enzymes in benign pancreatic hyperenzymemia. Clin Gastroenterol Hepatol. 2007 Jan;5(1):70-4. doi: 10.1016/j.cgh.2006.09.035.
80. Gullo L. Benign pancreatic hyperenzymemia. Dig. Liver Dis. 2007 Jul;39(7):698-702. doi: 10.1016/j.dld.2007.03.005.
81. Cook LJ, Musa OA, Case RM.Intracellular transport of pancreatic enzymes. Scand J Gastroenterol. 1996:219:1-5. doi: 10.3109/00365529609104990.
82. Rycyk A, Furtak P, Mądro A, Kasztelan-Szczerbińska B, Cichoż-Lach H. Gullo’s syndrome - what do we know? Prz Gastroenterol. 2021;16(3):181-183. doi: 10.5114/pg.2020.101133.
83. Camões G, Ferreira DM, Santos A, Santos L. Asymptomatic Elevation of Pancreatic Enzymes: A Case of Gullo’s Syndrome. Cureus. 2023 Sep 4;15(9): e44665. doi: 10.7759/cureus.44665.
84. Yang BL, Wu WC, Su CW, Wu JC, Yeh C, Lee SD. Healthy Chinese with benign pancreatic hyperenzymemia. J Chin Med Assoc. 2015 Oct;78(10):623-6. doi: 10.1016/j.jcma.2015.05.011.
85. Catanzaro R, Sciuto M, Adamo G, Guarrera M, Marotta F. Benign pancreatic hyperenzymemia-Gullo’s syndrome: focus on this clinical challenge. A monocentric retrospective study. Minerva Med. 2019 Dec;110(6):490-498. doi: 10.23736/S0026-4806.19.06046-4.
86. Humphries LL, Adams LJ, Eckfeldt JH, Levitt MD, McClain CJ. Hyperamylasemia in patients with eating disorders. Ann Intern Med. 1987 Jan;106(1):50-2. doi: 10.7326/0003-4819-106-1-50.
87. Gwirtsman HE, Kaye WH, George DT, Carosella NW, Greene RC, Jimerson DC. Hyperamylasemia and its relationship to binge-purge episodes: development of a clinically relevant laboratory test. J Clin Psychiatry. 1989 Jun;50(6):196-204.
88. Hempen I, Lehnert P, Fichter M, Teufel J. Hyperamylasemia in anorexia nervosa and bulimia nervosa. Indication of a pancreatic disease? Dtsch Med Wochenschr. 1989 Dec 8;114(49):1913-6. doi: 10.1055/s-2008-1066848.
89. Scheutzel P, Gerlach U. Alpha-amylase isoenzymes in serum and saliva of patients with anorexia and bulimia nervosa. Z Gastroenterol. 1991 Jul;29(7):339-45.
90. Kinzl J, Biebl W, Herold M. Significance of vomiting for hyperamylasemia and sialadenosis in patients with eating disorders.Int J Eat Disord. 1993 Jan;13(1):117-24. doi: 10.1002/1098-108x(199301)13:1<117:: aid-eat2260130114>3.0.co;2-8.
Review
For citations:
Dubtsova E.A., Vinokurova L.V., Bordin D.S. Pancreatic and non-pancreatic causes of hyperamylasemia. Experimental and Clinical Gastroenterology. 2025;(12):18-27. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-244-12-18-27
Views:
794
JATS XML
Email this article 
